Kura Oncology, Inc. — Earnings Quality Grade F
KURA · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 34 days (14 → 48)
Small-cap context: DSO swings on a small revenue base are more often quarterly customer-mix effects than red flags.
AR growth 327.4% exceeds revenue growth 25.2%
Revenue grew 25.2% but CFFO declined -147.7%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
Insufficient data
CapEx growth 1306.4% is >2x revenue growth 25.2%
SG&A/Gross Profit = 177.9%, exceeds 70%
Gross margin 99.9%, change -0.1pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.1B)
Accruals ratio = -29.1%. Low accruals
Cash $0.7B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -200.8x (<2x). Financial stress
Other assets grew 85.4% vs revenue 25.2%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
M-Score = -1.17 (> -1.78). LIKELY MANIPULATOR
Small-cap context: Beneish M-Score was calibrated on large-caps; small-cap DSO/inventory volatility mechanically inflates it.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25